Friday, April 14, 2017

FDA Rejects Eli Lilly and Incyte Drug

Eli Lilly and Incyte said the U.S. Food and Drug Administration didn’t approve their new drug application for a rheumatoid arthritis treatment that some analysts estimate could generate more than $2 billion in annual sales.

from WSJ.com: US Business http://ift.tt/2pjXM0k
via IFTTT

No comments:

Post a Comment